帕博利珠单抗联合仑伐替尼对比卡铂紫杉醇一线治疗晚期或复发性子宫内膜癌的Markov分析
本研究采用Markov模型,从医疗保健部门视角模拟晚期或复发性子宫内膜癌患者(MSS或MSI-high)接受帕博利珠单抗/仑伐替尼(P/L)对比卡铂/紫杉醇(C/T)一线治疗的成本效果。MSS队列中P/L增加成本212,670美元并减少0.28 QALY;MSI-high队列中P/L增加成本313,487美元并增加0.11 QALY,ICER为2,849,882美元/QALY。结论:MSS中P/L成本更高且结局更差,MSI-high中P/L改善生存但当前价格下不具成本效果。
要点
- MSS队列中P/L较C/T增加成本212,670美元且减少0.28 QALY。
- MSI-high队列中P/L较C/T增加成本313,487美元且增加0.11 QALY。
- 新药价格需下降85%至每周期2817美元才达15万美元/QALY阈值。
核心结论
- MSS模型中P/L较C/T增加成本并恶化结局;MSI-high模型中P/L改善生存和QALY但当前价格下不具成本效果。
研究设计与样本
- Markov模型模拟晚期或复发性子宫内膜癌患者(MSS或MSI-high)的治疗结局,采用医疗保健部门视角,时间范围3年,年贴现率3%。
- 模型输入的成本、健康效用和临床估计来自文献包括GOG0209和KEYNOTE-146数据。
主要发现
- MSS队列中P/L较C/T增加治疗成本212,670美元并减少0.28 QALY每患者。
- MSI-high队列中P/L较C/T增加成本313,487美元并增加0.11 QALY每患者,ICER为2,849,882美元/QALY。
- 敏感性分析发现新药价格是ICER的最重要决定因素,需下降85%至每周期2817美元以达到150,000美元/QALY阈值。
关键数值与推荐
- MSS队列:P/L对比C/T,成本增加212,670美元,QALY减少0.28。
- MSI-high队列:P/L对比C/T,成本增加313,487美元,QALY增加0.11,ICER 2,849,882美元/QALY。
- 新药价格需下降85%至每周期2817美元以达到150,000美元/QALY阈值。
临床怎么用
- 在MSS型晚期或复发性子宫内膜癌一线治疗中,P/L较C/T成本更高且结局更差。
- 在MSI-high型中P/L可改善生存和QALY,但当前价格下不具成本效果,需大幅降价才可能达到常用支付阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the cost effectiveness of pembrolizumab/lenvatinib (P/L) versus standard-of-care carboplatin/paclitaxel (C/T) as first-line systemic therapy for patients with advanced/recurrent endometrial cancer. METHODS: We designed a Markov model to simulate treatment outcomes for advanced/recurrent endometrial cancer patients whose tumors are either microsatellite stable (MSS) or have high microsatellite instability (MSI-high). We adopted a healthcare sector perspective for the analysis. Model inputs for costs, health utility, and clinical estimates were obtained from the literature including data from GOG0209 and KEYNOTE-146. Primary outcomes included costs of care, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER). The time-horizon was three years and the discount rate was 3% annually. RESULTS: In a MSS cohort, compared to C/T, first-line treatment with P/L increased treatment costs by $212,670 and decreased QALYs by 0.28 per patient. In a MSI-high cohort, compared to C/T, P/L increased costs by $313,487 and increased QALYs by 0.11 per patient, representing an ICER of $2,849,882 per QALY. Sensitivity analyses found that the price of the new drugs was the most important determinant of the ICER and that the price of the new drugs would need to decrease by 85% to $2817 per cycle to reach a $150,000/QALY threshold. CONCLUSION: In the MSS model, we found that first-line therapy for advanced or recurrent endometrial cancer with P/L increased costs and worsened outcomes compared to C/T. In the MSI-high model, P/L improved survival and QALYs compared to C/T but was not cost-effective at the current cost of the drugs.
引用
- Ackroyd SA, Huang ES, Kurnit KC, et al. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021. PMID: 34103196. doi:10.1016/j.ygyno.2021.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。